Significance of 18 F-fluorodeoxyglucose PET/computed tomography in the initial staging of malignant peritoneal

Hui Zhang1,2, Lifang Pang3,4, Jun Hou5

  • 1Department of Nuclear Medicine, Zhongshan Hospital (Xiamen), Fudan University, Fujian.

Abstract

Insights

18F-fluorodeoxyglucose PET/CT (FDG PET/CT) aids in staging malignant peritoneal mesothelioma (MPeM). This imaging technique shows high accuracy for TNM staging and can help differentiate between mesothelioma subtypes, informing treatment strategies.

Area of Science:

  • Oncology
  • Radiology
  • Nuclear Medicine

Background:

  • Malignant peritoneal mesothelioma (MPeM) is a rare and aggressive cancer.
  • Accurate staging and differentiation are crucial for effective treatment planning.

Purpose of the Study:

  • To evaluate the role of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) in staging and differentiating MPeM.
  • To assess the diagnostic accuracy of FDG PET/CT for tumor staging and metastasis detection.

Main Methods:

  • Retrospective analysis of clinical and imaging data from 42 MPeM patients who underwent FDG PET/CT.
  • Determination of Standardized Uptake Values (SUVmax), Metabolic Tumor Volume (MTV), and Total Lesion Glycolysis (TLG).
  • Assessment of Tumor-Node-Metastasis (TNM) staging and Peritoneal Cancer Index by experienced readers.

Main Results:

  • FDG PET/CT demonstrated a diagnostic accuracy of 72.2% for T stage and 94.4% for TNM stage.
  • SUVmax and MTV were significantly lower in epithelial MPeM compared to nonepithelioid types.
  • Lymph node metastasis was more frequent in biphasic MPeM, while sarcomatoid MPeM showed more frequent metastasis.

Conclusions:

  • FDG PET/CT can significantly improve the accuracy of TNM staging for MPeM.
  • SUVmax values may vary slightly based on MPeM pathology type.
  • FDG PET/CT provides whole-body visualization, aiding in treatment strategy development.